title: Influence of G1359A polimorphysm of the cannabinoid receptor gene (CNR1) on insulin resistance and adipokines in patients with non alcoholic fatty liver disease.
abstract: BACKGROUND
  Considering the evidence that endogenous cannabinoid system plays a role in metabolic aspects of body weight and metabolic syndrome components such as non alcoholic fatty liver disease (NAFLD). The aim of our study was to investigate the influence of this polymorphism on insulin resistance, liver histological changes, anthropometric parameters and adipocytokines in patients with NAFLD.
  
  
  METHODS
  A population of 71 patients with NAFLD was recruited in a cross sectional study. A biochemical analysis of serum was measured. Genotype of G1359A polymorphism of CB1 receptor gene CB1 receptor was studied. Forty one patients (36.9%) had the genotype G1359G (wild type group) and twenty nine (26.1%) patients G1359A or A1359A (mutant type group).
  
  
  RESULTS
  Twenty four 24 patients (32,3%) had a Brunt grade > 4 and 12 patients (17%) had a significative fibrosis (F > = 2). HOMA values were higher in wild type group than mutant type group. Adiponectin and visfatin levels were higher in mutant type group. Moreover, TNF-alpha and resistin levels were higher in wild type group than mutant type group. Patients with mutant genotype showed less frequently elevated levels of AST. AST > 40 UI/L was detected in 28.5% of patients in the mutant vs. 53% of patients with wild genotype, p < 0.05. Patients with mutant type group presented a percentage of Brunt grade > = 4 less frequently than patients with wild type group (28.5%vs 7.1%).
  
  
  CONCLUSIONS
  A variant of the polymorphism G1359A CBR1 is associated with lower levels of HOMA, TNF-alpha, resistin and higher levels of adiponectin than patients with the wild variant of this polymorphism. Besides, patients with A allele variant shown lower Brunt grade in liver biopsy.
authors.affiliation: Gastroenterology Department, Hospital Clínico Universitario of Valladolid, Valladolid, España.
authors.forename: R
authors.initials: R
authors.lastname: Aller
authors.forename: D A
authors.initials: DA
authors.lastname: de Luis
authors.forename: D
authors.initials: D
authors.lastname: Pacheco
authors.forename: M C
authors.initials: MC
authors.lastname: Velasco
authors.forename: R
authors.initials: R
authors.lastname: Conde
authors.forename: O
authors.initials: O
authors.lastname: Izaola
authors.forename: M
authors.initials: M
authors.lastname: González Sagrado
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D000886:Anthropometry; D001706:Biopsy; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000502:physiology; D005234:Fatty Liver / Q000097:blood / Q000235:genetics* / Q000473:pathology; D005260:Female; D005838:Genotype; D006801:Humans; D007333:Insulin Resistance / Q000235:genetics*; D008099:Liver / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics*
chemical_list: D054392:Adipokines; D001786:Blood Glucose; D043884:Receptor, Cannabinoid, CB1